Compare ONL & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | SEER |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 106.0M |
| IPO Year | N/A | 2020 |
| Metric | ONL | SEER |
|---|---|---|
| Price | $2.06 | $1.83 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 284.6K | 156.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | $16,376,999.00 |
| Revenue This Year | N/A | $22.37 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.11 |
| 52 Week Low | $1.46 | $1.62 |
| 52 Week High | $4.25 | $2.59 |
| Indicator | ONL | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 28.36 |
| Support Level | $1.92 | $1.85 |
| Resistance Level | $2.31 | $2.02 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 26.53 | 7.32 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.